MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer

Cai, Yu; Ruan, Jian; Yao, Xueqing; Zhao, Liang; Wang, Baocheng

doi:10.3892/or.2017.5548

Cited by 21 publications

(19 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six negative-relevant miRNAs were miR-187, miR-9-3, miR-490, miR-1258, miR-551a and miR-665; among these miRNAs, miR-187 has been found to be overexpressed in ovarian cancers 20 , can induce epithelial-mesenchymal transition (EMT) by targeting PTRF in non-small cell lung cancer 21 and promotes the growth and metastasis of gastric cancer by inhibiting FOXA2 22 . this result indicated that miR-187 possessed the potential to be a candidate for LIHC therapy.…”

Section: Discussionmentioning

confidence: 99%

A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy

Yang

Xiang³

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Liver hepatocellular carcinoma (LIHC) is the most common type of primary liver cancer. In the current study, genome-wide miRNA-Seq and mRNA profiles in 318 LIHC patients derived from The Cancer Genome Atlas (TCGA) were analysed to identify miRNA-based signatures for LIHC prognosis with survival analysis and a semi-supervised principal components (SPC) method. A seven-miRNA signature was confirmed for overall survival (OS) prediction by comparing miRNA profiles in paired primary tumour and solid tumour normal tissues. Thereafter, a linear prognostic model that consisted of seven miRNAs was established and used to divide patients into high- and low-risk groups according to prognostic scores. Subsequent Kaplan-Meier analysis revealed that the seven-miRNA signature correlated with a good predictive clinical outcome for 5-year survival in LIHC patients. Additionally, this miRNA-based prognostic model could also be used for OS prognosis of LIHC patients in early stages, which could guide the future therapy of those patients and promote the OS rate. Moreover, the seven-miRNA signature was an independent prognostic factor. In conclusion, this signature may serve as a prognostic biomarker and guide LIHC therapy, and it could even be used as an LIHC therapeutic target in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy

Yang

Xiang³

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In lung cancer, PTRF inhibits the EMT process and suppresses the cell proliferation and metastasis (20). The downregulation of PTRF is associated with dysregulation of miRNAs and DNA methylation in cancer cells (20,30). Via bioinformatics analysis, the present study identified that PTRF is a potential target of miR-1301-3p.…”

Section: Discussionmentioning

confidence: 69%

“…For example, PTRF overexpression restores caveolae formation, reduces matrix metalloproteinase-9 expression and inhibits the migration of metastatic prostate cancer cells (29). In lung cancer, PTRF inhibits the EMT process and suppresses the cell proliferation and metastasis (20). The downregulation of PTRF is associated with dysregulation of miRNAs and DNA methylation in cancer cells (20,30).…”

Section: Discussionmentioning

confidence: 99%

miR‑1301‑3p promotes the proliferation and migration of lung cancer cells via direct repression of polymerase I and transcript release factor

Shen

Chen

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Aberrant expression of microRNAs (miRNAs or miRs) is associated with a number of human diseases, including lung cancer. Although numerous differentially expressed miRNAs have been identified in lung cancer via microarray and sequencing methods, to the best of our knowledge, only a small portion of these miRNAs have been experimentally verified. In the present study, miR-1301-3p expression levels in lung tumor tissues and lung cancer cells were measured by reverse transcription-quantitative PCR (RT-qPCR) and by analyzing previously published data. Cell Counting Kit-8 and Transwell assays were used to analyze the function of miR-1301-3p in lung cancer tissues and cells. Bioinformatics analysis, RT-qPCR, western blotting and a dual-luciferase reporter assay were performed to investigate the mechanism of miR-1301-3p in lung cancer cells. It was identified that miR-1301-3p is an upregulated miRNA in lung cancer via analyzing previously published microarray and The Cancer Genome Atlas-lung squamous cell carcinoma project data, and the upregulation of miR-1301-3p was confirmed in collected clinical samples and cells. Inhibition of miR-1301-3p suppressed lung cancer cell proliferation and migration. In addition, miR-1301-3p inhibition upregulated E-cadherin, an epithelial cell maker, and downregulated vimentin, a mesenchymal cell marker. Using bioinformatics analysis, it was revealed that polymerase I and transcript release factor (PTRF) is a target of miR-1301-3p. RT-qPCR, western blotting and dual-luciferase reporter assays demonstrated that PTRF is targeted by miR-1301-3p in lung cancer cells. The rescue experiments indicated that silencing PTRF could attenuate the inhibition of cell proliferation and migration induced by miR-1301-3p inhibitor in lung cancer cells. Furthermore, a strong negative correlation between miR-1301-3p and PTRF mRNA was identified in clinical samples. In summary, the present data highlight the involvement of miR-1301-3p in the proliferation and migration of lung cancer cells, indicating that miR-1301-3p may be a promising biomarker for lung cancer.

show abstract

“…These data indicate that miR-187 plays an important role in cancer development [18]. Cai et al [33] found that miR-187 promotes cell migration and epithelial-mesenchymal transition (EMT) by targeting polymerase I and transcript release factor (PTRF) in NSCLC, and miR-187 potentially plays an oncogenic role in the progression of NSCLC.…”

Section: Discussionmentioning

confidence: 97%

MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9

Liang

et al. 2019

Bioengineered

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is the main pathological type of lung cancer and has a low overall five-year survival rate. miR-187 has been reported to play major roles in various tumor types. In this study, we explored the impact of miR-187 on NSCLC. qRT-PCR results demonstrated that miR-187 expression is lower in NSCLC and cancer cells than normal tissues and normal lung cells. miR-187 expression levels are associated with tumor size, TNM stage and overall survival rate. MTS and colony formation assays showed that high miR-187 expression inhibits NSCLC cell proliferation and colony formation ability, and flow cytometry showed that miR-187 overexpression induces cell cycle arrest at the G0/G1 phase. A luciferase reporter assay showed that FGF9 is a target of miR-187. miR-187 overexpression reduces the expression of FGF9, cyclin D1 CDK4 and CDK6. Therefore, miR-187 may present a new NSCLC treatment target by regulates cyclins-related protein expression.

show abstract

MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer

Cited by 21 publications

References 47 publications

A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy

A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy

miR‑1301‑3p promotes the proliferation and migration of lung cancer cells via direct repression of polymerase I and transcript release factor

MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9

Contact Info

Product

Resources

About